Enzon Pharmaceuticals Inc.

Jeffrey H. Buchalter , has served as the Company s President and Chief Executive Officer since December 2004, and as Chairman of the Company s Board of Directors since September 2004. Having held several key positions at a number of multinational pharmaceutical companies, Mr. Buchalter has more than 20 years of industry experience. Prior to joining the Company, Mr. Buchalter served as President and Chief Executive Officer of ILEX Oncology, Inc. from January 2002 through December 2004 after serving as President from September 2001 through December 2001. During his tenure at ILEX, Mr. Buchalter led the company s transformation from a drug development contract research organization to a product-driven pharmaceutical company, with a high quality oncology franchise and established commercialization expertise. ILEX Oncology was acquired in December 2004 by Genzyme Corporation for $1.1 billion. Throughout his career, he has directed the development and commercialization of a number of innovative pharmaceutical products which meet the needs of healthcare professionals and patients worldwide. As Group Vice President and Head of the Worldwide Oncology Franchise at Pharmacia Corporation from 1997 to 2000, Mr. Buchalter was pivotal in strategically building the company s global oncology franchise through new product approvals and launches, as well as the 1999 acquisition of Sugen, Inc., a transaction that enhanced Pharmacia s drug discovery and development capabilities as well as its oncology pipeline. Before joining Pharmacia, Mr. Buchalter held positions at Wyeth (formerly American Home Products) and Schering-Plough Corporation. From 1993 to 1997, as Group Director for the women s healthcare business of American Home Products, Mr. Buchalter played a key role in the life cycle management of its multibillion-dollar drug Premarin (conjugated estrogens tablets, USP), and helped to develop and commercialize the hormone replacement therapy Prempro (conjugated estrogens/medroxyprogesterone acetate tablets). While at Schering-Plough Corporation in the late 1980s and early 1990s, he led the launch of Intron A (interferon alpha-2b), one of the first cytokines to be approved for hairy cell leukemia. Among his career honors, Mr. Buchalter received the American Cancer Society s Joseph F. Buckley Memorial Award for commitment to cancer control and involvement in the oncology pharmaceutical field. Additionally, former President George H.W. Bush invited him to serve as a collaborating partner in the National Dialogue on Cancer. Mr. Buchalter has been a strong proponent in accelerating the development of novel new therapeutics for children diagnosed with cancer. He has been invited to participate in a selective panel of experts addressing this global challenge. Mr. Buchalter received his B.S. in finance from Seton Hall University, and an M.B.A. in marketing from Temple University. Mr. Buchalter also serves as a member of the Board of Directors of TopoTarget A/S, a publicly held Danish biopharmaceutical company, and as Chairman of the Board of Directors of MacroGenics Inc., a private, venture-backed biotechnology company. Mr. Buchalter serves as Chairman of the Board of Trustees of The National Childhood Cancer Foundation (NCCF). The NCCF is a non-profit, public benefit charity dedicated to support research to conquer childhood cancer. The Vision of NCCF is to eliminate cancer as the cause of more deaths during childhood than any other disease. The Mission of NCCF is to support nationwide, multi institution, cooperative research and public policy to benefit children and adolescents with cancer, survivors and their families.

Dr. Ivan Horak has served as Enzon’s executive vice president of research and development and chief scientific officer since September 2005. In this role, he is responsible for all aspects of Enzon’s research and development, regulatory affairs, and quality assurance activities. Prior to joining Enzon, Dr. Horak served as Executive Vice President and Chief Scientific Officer of Immunomedics, Inc. Before joining Immunomedics, Dr. Horak was employed by Pharmacia as a Vice President for Clinical Oncology, where he helped direct the global development of oncology compounds from 1999 to 2002, including Camptosar® for metastatic colorectal cancer. From 1996 to 1999, Dr. Horak held a variety of clinical research positions at Janssen Research Foundation, a subsidiary of the Johnson & Johnson Company, including International Director for Clinical Research and Development, Oncology. Prior to joining Janssen, Dr. Horak spent nine years at the NCI where he most recently served as a cancer expert for the Metabolism Branch. In addition to over 50 scientific publications, Dr. Horak is a member of several prominent medical societies and has served on various committees for the American Association for Cancer Research and the International Union Against Cancer. He also serves on the editorial board of the prestigious journal, Cancer Research. Dr. Horak received his M.D. degree from the University of Komenius, Bratislava, Czechoslovakia.

Paul Davit has served as Enzon’s executive vice president, human resources since April 2005. From March 2002 to April 2005, Mr. Davit served as Enzon’s senior vice president, human resources. Paul Davit Executive Vice President, Human Resources For more than 20 years, Mr. Davit has directed numerous human resource functions within various corporate settings both as a member of executive management as well as in a consulting capacity. Prior to joining Enzon, Mr. Davit ran a human resources consulting practice. Previously, Mr. Davit worked at Caliber Associates and spent over 12 years with Rhône-Poulenc Rorer, where he served as vice president of human resources for RPR Gencell, Rhône-Poulenc Rorer’s start-up biotechnology division and as vice president of human resources for the North American Pharmaceuticals division. Mr. Davit began his career as a compensation consultant with the Hay Group. Mr. Davit received a B.S. in psychology and sociology, an M.S. in environmental science, and an M.B.A. in management sciences, all from Drexel University. Mr. Davit is certified as a Senior Professional in Human Resources by the Human Resources Certification Institute.

Ralph del Campo has served as Enzon’s executive vice president, operations since April 2005. Mr. del Campo is responsible for overseeing all aspects of Enzon’s manufacturing, quality assurance and control, materials management, facilities, and engineering functions. Mr. Del Campo has over 30 years of diverse industry experience, including serving as Enzon’s senior vice president, operations from October 2002 to April 2005. Prior to joining Enzon, Mr. del Campo was the head of the North American operations of Elan Corporation, plc. As part of Elan’s acquisition of The Liposome Company, Mr. del Campo directed the start-up, scale-up, and ongoing operation of a sterile injectable manufacturing facility in Indianapolis. Mr. del Campo also spent over 17 years in various senior operations management positions at Bristol-Myers Squibb, where he directed the growth of new laboratories, computerized manufacturing systems, and domestic operations effectiveness. Mr. del Campo received his B.S. in chemical engineering from the Newark College of Engineering and an M.B.A. in pharmaceutical marketing from Fairleigh Dickinson University.

In late January 2009, Dr. Denner was interviewed by Messrs. LeBuhn, Micati and Salisbury, and Professor Mulligan was interviewed by Drs. Ando and Geltosky and, at their invitation, Dr. Ivan Horak, the Company s Executive Vice President, Research and Development and Chief Scientific Officer. At a meeting of the Governance and Nominating Committee held on January 28, 2009, the Committee determined to recommend to the Board the nominations of Dr. Denner and Professor Mulligan for election as Class I Directors at the Annual Meeting. At a meeting of the Board held later that day, the Board determined to accept the recommendation of the Governance and Nominating Committee and nominated Dr. Denner and Professor Mulligan for election as Class I Directors at the Annual Meeting. At the request of the Icahn Group, the Board committed to the Icahn Group that if, for any reason, the Board subsequently determined not to nominate both Dr. Denner and Professor Mulligan, or to nominate any persons in addition to Dr. Denner and Professor Mulligan, for election as Class I Directors at the Annual Meeting, the Company would give the Icahn Group prompt written notice thereof and the Company would take all necessary action to permit the Icahn Group to nominate persons named in a notice of nomination for election to the Board which the Icahn Group would deliver to the Company on or before the close of business on the tenth day following the date on which the Icahn Group received such written notice from the Company.

Victor P. Micati has served as a director of the Company since November 2004. Mr. Micati is a retired senior executive of Pfizer Inc. In 1999, Mr. Micati retired from Pfizer where he most recently had served as Executive Vice President of the Pharmaceutical Group of Pfizer and Vice President of Pfizer Inc. Mr. Micati first joined Pfizer in 1965 and over a 34-year career served in numerous capacities, including: President of European Operations; Executive Vice President of Pfizer Europe; Senior Vice President, Pharmaceuticals; Vice President of Pharmaceutical Development, Pfizer International; and Vice President of Marketing, Pfizer Laboratories. Mr. Micati also served as a member of the Pfizer International Board of Directors. Mr. Micati is currently a consultant to the pharmaceutical industry and is a member of the Board of Trustees of the Monterey Institute of International Studies.

Robert C. Salisbury has served as a director of the Company since May 2005. In 1998, Mr. Salisbury retired from Pharmacia & Upjohn, Inc., where he had most recently served as Executive Vice President and Chief Financial Officer. Previously, Mr. Salisbury served as Executive Vice President, Finance and Chief Financial Officer at The Upjohn Company. Mr. Salisbury first joined The Upjohn Company in 1974 and over a career of more than 20 years, he served in various management posts in finance and strategic planning.

Craig Tooman has served as Enzon’s executive vice president of finance and chief financial officer since, 2005. In this role, he is responsible for all financial aspects of Enzon, in addition to the Company’s investor relations, public relations, and strategic planning functions. Mr. Tooman joined Enzon in January 2005 as the Company’s executive vice president of strategic planning and corporate communications. Mr. Tooman has nearly 20 years of industry experience, having worked extensively in diverse pharmaceutical positions including investor communications, strategic planning, finance, marketing, and sales. Prior to joining Enzon, he served as senior vice president of strategic planning and corporate communications of ILEX Oncology, Inc, which was acquired by Genzyme in December 2004. While at ILEX, Mr. Tooman managed the formation of ILEX’s first comprehensive strategic plan and the restructuring of the company’s clinical development activities to drive the company’s transformation from a drug development contract research organization into a product-driven pharmaceutical company. Mr. Tooman was also responsible for managing ILEX’s investment banking relationships, including playing a critical role in the merger of ILEX and Genzyme, a $1 billion transaction. Before joining ILEX, Mr. Tooman worked at Pharmacia Corporation where he progressed through positions of increasing responsibility in investor relations, including vice president of investor relations. In this role, he was responsible for global investor relations activities and spearheaded communications with the financial community on the Pharmacia and Upjohn/Monsanto merger. Additionally, under his leadership the Investor Relations unit of Pharmacia won four of the largest awards of distinction in Investor and Public Relations. He has also held various management positions in Europe and Japan. Mr. Tooman received his B.A. in economics from Kalamazoo College and an M.B.A. in finance from the University of Chicago.

Dr. Jack Geltosky was appointed director of Enzon in May 2008. He has more than 25 years of pharmaceutical experience and has extensive expertise in developing business strategies for acquiring proprietary, breakthrough technologies across many therapeutic areas. In 2007, he joined Arizona Technology Enterprises as their Senior Vice President of Business Development, Life Sciences. Dr. Geltosky has worked for pharmaceutical companies such as Bristol-Myers Squibb, Smithkline Beecham Pharmaceuticals and Johnson & Johnson, where he collaborated closely with R&D and Marketing. He earned a Bachelor of Science degree in Chemistry from Memphis State University, graduating magna cum laude, and he earned his Ph.D. in Biochemistry from California Institute of Technology. Additionally, Dr. Geltosky completed his NIH Postdoctoral Fellowship and American Cancer Society Fellowship, California Division at the Scripps Research Institute in La Jolla, CA.

Dr. Mulligan is the Mallinckrodt Professor of Genetics at Harvard Medical School and Director of the Harvard Gene Therapy Initiative. Dr. Mulligan received his B.S. from the Massachusetts Institute of Technology and his Ph.D. from the Department of Biochemistry at Stanford University School of Medicine. After receiving postdoctoral training at the Center for Cancer Research at MIT, Dr. Mulligan joined the MIT faculty and subsequently was appointed Professor of Molecular Biology and Member of the Whitehead Institute for Biomedical Research before moving to Children's Hospital and Harvard in 1996. Dr. Mulligan has been associated with a number of biotechnology companies, including Somatix Therapy Corporation (as founder, director, Scientific Advisory Board member and Chief Scientific Officer), Cell Genesys, Inc. (as Scientific Advisory Board member) and ImClone Systems Incorporated (as director and Scientific Advisory Board member). Dr. Mulligan is currently a director of Enzon Pharmaceuticals, Inc.